KR20010042307A - 피롤로[1,2-a]피라진 sPLA2 억제제 - Google Patents

피롤로[1,2-a]피라진 sPLA2 억제제 Download PDF

Info

Publication number
KR20010042307A
KR20010042307A KR1020007010855A KR20007010855A KR20010042307A KR 20010042307 A KR20010042307 A KR 20010042307A KR 1020007010855 A KR1020007010855 A KR 1020007010855A KR 20007010855 A KR20007010855 A KR 20007010855A KR 20010042307 A KR20010042307 A KR 20010042307A
Authority
KR
South Korea
Prior art keywords
pyrazin
ethyl
methyl
compound
oxamoylpyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020007010855A
Other languages
English (en)
Korean (ko)
Inventor
오따니미쯔아끼
후지마사히로
오까다데쯔오
Original Assignee
시오노 요시히코
시오노기세이야쿠가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시오노 요시히코, 시오노기세이야쿠가부시키가이샤 filed Critical 시오노 요시히코
Publication of KR20010042307A publication Critical patent/KR20010042307A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020007010855A 1998-03-31 1999-03-31 피롤로[1,2-a]피라진 sPLA2 억제제 Ceased KR20010042307A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP98-85997 1998-03-31
JP8599798 1998-03-31
JP98-244735 1998-08-31
JP24473598 1998-08-31
PCT/JP1999/001670 WO1999051605A1 (en) 1998-03-31 1999-03-31 PYRROLO[1,2-a]PYRAZINE sPLA2 INHIBITOR

Publications (1)

Publication Number Publication Date
KR20010042307A true KR20010042307A (ko) 2001-05-25

Family

ID=26427020

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007010855A Ceased KR20010042307A (ko) 1998-03-31 1999-03-31 피롤로[1,2-a]피라진 sPLA2 억제제

Country Status (11)

Country Link
US (1) US6407104B1 (cg-RX-API-DMAC7.html)
EP (1) EP1066290A1 (cg-RX-API-DMAC7.html)
JP (1) JP4412521B2 (cg-RX-API-DMAC7.html)
KR (1) KR20010042307A (cg-RX-API-DMAC7.html)
CN (1) CN1303384A (cg-RX-API-DMAC7.html)
AU (1) AU3054399A (cg-RX-API-DMAC7.html)
BR (1) BR9909345A (cg-RX-API-DMAC7.html)
CA (1) CA2326522A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0102981A3 (cg-RX-API-DMAC7.html)
NO (1) NO20004881L (cg-RX-API-DMAC7.html)
WO (1) WO1999051605A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69931963D1 (de) * 1998-10-14 2006-07-27 Shionogi & Co Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden
JP4636521B2 (ja) 1999-07-19 2011-02-23 塩野義製薬株式会社 sPLA2阻害作用を有する三環系化合物
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
AU7559600A (en) * 1999-10-15 2001-04-23 Shionogi & Co., Ltd. V type and/or x type spla2 inhibitors
WO2001036420A1 (en) * 1999-11-15 2001-05-25 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an spla2- inhibiting effect
WO2002000256A1 (fr) 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes contre la cirrhose
AU2001267823A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
AUPQ876400A0 (en) * 2000-07-14 2000-08-03 University Of Queensland, The Compositions and method of using them
JP2004505982A (ja) * 2000-08-04 2004-02-26 イーライ・リリー・アンド・カンパニー 新規なsPLA2インヒビター
TWI314457B (cg-RX-API-DMAC7.html) * 2001-03-19 2009-09-11 Shionogi & Co
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
DE10155727A1 (de) * 2001-11-13 2003-05-28 Morphochem Ag Serin Protease Inhibitoren
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
US7345178B2 (en) * 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
TW200916472A (en) * 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
CN105622616A (zh) * 2016-02-25 2016-06-01 上海雅本化学有限公司 一种4-氯吡咯并嘧啶的制备方法
US20250129010A1 (en) * 2021-09-17 2025-04-24 Mitsui Chemicals, Inc. Method for producing (meth)acrylamide compound

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109311A0 (en) 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
EP1950200B1 (en) 1994-04-01 2012-01-11 Eli Lilly And Company [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
US6645976B1 (en) * 1994-07-21 2003-11-11 Eli Lilly And Company Indolizine SPLA2inhibitors
US6214876B1 (en) 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
IL124871A (en) 1995-12-13 2002-04-21 Lilly Co Eli Naphthyl glyoxamides and medicinal preparations containing them, as inhibitors of sPLA2
DE69614232T2 (de) 1995-12-13 2002-01-10 Eli Lilly And Co., Indianapolis Naphthyl-Acetamide als sPLA2-Inhibitoren
KR20000049210A (ko) 1996-10-30 2000-07-25 피터 지. 스트링거 치환된 트리시클릭류
US6353128B1 (en) 1996-12-03 2002-03-05 Eli Lilly And Company Phenyl acetamides as sPLA2 inhibitors
US5916922A (en) 1996-12-03 1999-06-29 Eli Lilly And Company Phenyl glyoxamides as SPLA2 inhibitors
ID18983A (id) 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
TW455581B (en) 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides

Also Published As

Publication number Publication date
US6407104B1 (en) 2002-06-18
HUP0102981A3 (en) 2002-10-28
CN1303384A (zh) 2001-07-11
BR9909345A (pt) 2000-12-12
EP1066290A1 (en) 2001-01-10
JP2002530268A (ja) 2002-09-17
AU3054399A (en) 1999-10-25
CA2326522A1 (en) 1999-10-14
HUP0102981A2 (hu) 2002-01-28
NO20004881D0 (no) 2000-09-28
WO1999051605A1 (en) 1999-10-14
NO20004881L (no) 2000-11-28
JP4412521B2 (ja) 2010-02-10

Similar Documents

Publication Publication Date Title
JP4544446B2 (ja) sPLA2阻害作用を有するピロロ[1,2−b]ピリダジン誘導体
JP4623483B2 (ja) sPLA2阻害作用を有するピロロトリアジン誘導体
JPWO2001014378A1 (ja) sPLA2阻害作用を有するピロロトリアジン誘導体
JPWO1999059999A1 (ja) sPLA2阻害作用を有するピロロ[1,2−b]ピリダジン誘導体
JP4412521B2 (ja) sPLA2阻害作用を有するピロロ[1,2−a]ピラジン誘導体
ES2231526T3 (es) Ciclopentaindoles, composiciones que contienen dichos compuestos y procedimientos de tratamiento.
EP1395590B1 (en) Dihydropyrrolo¬1,2-a|indole and tetrahydropyrido¬1,2-a|indole derivatives as prostaglandin d2 receptor antagonists
JP5259592B2 (ja) Ep4受容体リガンドとしてのチオフェンカルボキサミド誘導体
JP5680146B2 (ja) Crth2受容体拮抗薬としての複素環化合物
JP3572617B2 (ja) ピラゾロピリジンアデノシン拮抗剤
JP4972644B2 (ja) Crth2受容体拮抗薬としてのインドール誘導体
AU753547B2 (en) Substituted tricyclics
JP2009543836A (ja) インドール化合物
JPWO2002000621A1 (ja) X型sPLA2阻害作用を有する化合物
US6756376B1 (en) Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities
JP4636521B2 (ja) sPLA2阻害作用を有する三環系化合物
JPWO2001005789A1 (ja) sPLA2阻害作用を有する三環系化合物
JP4636522B2 (ja) sPLA2阻害作用を有する三環式化合物
JPWO2001009130A1 (ja) sPLA2阻害作用を有する三環式化合物
JPWO2001036420A1 (ja) sPLA2阻害作用を有する三環性アザインドリジン誘導体
JP5841361B2 (ja) 三環性化合物及びそれを含有する医薬組成物
MXPA00009418A (en) PYRROLO[1,2-a]PYRAZINE sPLA2
MXPA00011018A (en) PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES HAVING sPLA2
JP2008528666A (ja) グリコーゲンホスホリラーゼ阻害活性を有するインダンアミド誘導体
CZ20003193A3 (cs) Sloučenina pyrrolo[l,2-a]pyrazinu, proléčivo, farmaceutický prostředek a metoda inhibující sPLA2

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20000929

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20021026

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20030127

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20021026

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I